ETFMG Treatments Testing and Advancements ETF
|
|
Schedule of Investments
|
|
December 31, 2023 (Unaudited)
|
|
|
|
COMMON STOCKS - 99.7%
|
|
Shares
|
|
|
Value
|
|
Canada - 4.4%
|
|
|
|
|
Biotechnology - 1.1%
|
|
|
|
|
|
|
Arbutus Biopharma Corp.(a)
|
|
|
42,518
|
|
|
$
|
106,295
|
|
XBiotech, Inc.(a)
|
|
|
7,717
|
|
|
|
30,868
|
|
|
|
|
|
|
|
|
137,163
|
|
Life Sciences Tools & Services - 3.3%
|
|
|
|
|
|
|
|
|
AbCellera Biologics, Inc.(a)(b)
|
|
|
73,571
|
|
|
|
420,090
|
|
Total Canada
|
|
|
|
557,253
|
|
|
|
|
|
|
|
|
|
|
Cayman Islands - 3.6%
|
|
|
|
|
|
Biotechnology - 3.6%
|
|
|
|
|
|
|
|
|
Zai Lab, Ltd. - ADR(a)(b)
|
|
|
16,653
|
|
|
|
455,126
|
|
|
|
|
|
|
|
|
|
|
France - 0.7%
|
|
|
|
|
|
Pharmaceuticals - 0.7%
|
|
|
|
|
|
|
|
|
Sanofi - ADR(b)
|
|
|
1,869
|
|
|
|
92,945
|
|
|
|
|
|
|
|
|
|
|
Germany - 5.6%
|
|
|
|
|
|
Biotechnology - 5.6%
|
|
|
|
|
|
|
|
|
BioNTech SE - ADR(a)(b)
|
|
|
6,789
|
|
|
|
716,511
|
|
|
|
|
|
|
|
|
|
|
Japan - 0.7%
|
|
|
|
|
|
Pharmaceuticals - 0.7%
|
|
|
|
|
|
|
|
|
Takeda Pharmaceutical Co., Ltd. - ADR(b)
|
|
|
6,176
|
|
|
|
88,132
|
|
|
|
|
|
|
|
|
|
|
Netherlands - 2.1%
|
|
|
|
|
|
Biotechnology - 2.1%
|
|
|
|
|
|
|
|
|
CureVac NV(a)(b)
|
|
|
56,774
|
|
|
|
239,019
|
|
InflaRx NV(a)(b)
|
|
|
14,929
|
|
|
|
24,334
|
|
|
|
|
|
|
|
|
263,353
|
|
Total Netherlands
|
|
|
|
263,353
|
|
|
|
|
|
|
|
|
|
|
United Kingdom - 5.9%
|
|
|
|
|
|
Biotechnology - 4.5%
|
|
|
|
|
|
|
|
|
Immunocore Holdings PLC - ADR(a)(b)
|
|
|
8,619
|
|
|
|
588,851
|
|
|
|
|
|
|
|
$
|
–
|
|
Pharmaceuticals - 1.4%
|
|
|
|
|
|
|
|
|
AstraZeneca PLC - ADR
|
|
|
1,353
|
|
|
|
91,124
|
|
GSK PLC - ADR
|
|
|
2,428
|
|
|
|
89,982
|
|
|
|
|
|
|
|
|
181,106
|
|
Total United Kingdom
|
|
|
|
769,957
|
|
|
|
|
|
|
|
|
|
|
United States - 76.7%(c)
|
|
|
|
|
|
Biotechnology - 44.0%(d)
|
|
|
|
|
|
|
|
|
AbbVie, Inc.
|
|
|
614
|
|
|
|
95,152
|
|
Alnylam Pharmaceuticals, Inc.(a)
|
|
|
4,052
|
|
|
|
775,592
|
|
Altimmune, Inc.(a)(b)
|
|
|
13,623
|
|
|
|
153,259
|
|
Arcturus Therapeutics Holdings, Inc.(a)
|
|
|
6,775
|
|
|
|
213,616
|
|
BioCryst Pharmaceuticals, Inc.(a)
|
|
|
51,928
|
|
|
|
311,049
|
|
CEL-SCI Corp.(a)(b)
|
|
|
12,672
|
|
|
|
34,468
|
|
Chimerix, Inc.(a)
|
|
|
22,538
|
|
|
|
21,693
|
|
Cue Biopharma, Inc.(a)
|
|
|
11,441
|
|
|
|
30,204
|
|
Dynavax Technologies Corp.(a)(b)
|
|
|
32,773
|
|
|
|
458,167
|
|
Emergent BioSolutions, Inc.(a)
|
|
|
13,135
|
|
|
|
31,524
|
|
Enanta Pharmaceuticals, Inc.(a)
|
|
|
5,339
|
|
|
|
50,240
|
|
Gilead Sciences, Inc.(b)
|
|
|
1,141
|
|
|
|
92,432
|
|
Gritstone bio, Inc.(a)
|
|
|
24,173
|
|
|
|
49,313
|
|
HilleVax, Inc.(a)
|
|
|
12,281
|
|
|
|
197,110
|
|
Icosavax, Inc.(a)
|
|
|
12,700
|
|
|
|
200,152
|
|
ImmunityBio, Inc.(a)(b)
|
|
|
123,495
|
|
|
|
619,945
|
|
Inovio Pharmaceuticals, Inc.(a)
|
|
|
69,214
|
|
|
|
35,299
|
|
Invivyd, Inc.(a)
|
|
|
27,919
|
|
|
|
110,001
|
|
Moderna, Inc.(a)
|
|
|
8,773
|
|
|
|
872,474
|
|
Novavax, Inc.(a)
|
|
|
30,118
|
|
|
|
144,566
|
|
Ocugen, Inc.(a)
|
|
|
65,034
|
|
|
|
37,395
|
|
Regeneron Pharmaceuticals, Inc.(a)(b)
|
|
|
106
|
|
|
|
93,099
|
|
Renovaro Biosciences, Inc.(a)
|
|
|
16,911
|
|
|
|
53,608
|
|
Vaxart, Inc.(a)(b)
|
|
|
38,548
|
|
|
|
22,080
|
|
Vaxcyte, Inc.(a)
|
|
|
8,778
|
|
|
|
551,258
|
|
Vaxxinity, Inc. - Class A(a)
|
|
|
32,136
|
|
|
|
27,316
|
|
Vir Biotechnology, Inc.(a)
|
|
|
34,107
|
|
|
|
343,116
|
|
|
|
|
|
|
|
|
5,624,128
|
|
Health Care Equipment & Supplies - 6.5%
|
|
|
|
|
|
|
|
|
Abbott Laboratories
|
|
|
838
|
|
|
|
92,239
|
|
Cue Health, Inc.(a)
|
|
|
39,206
|
|
|
|
6,371
|
|
Hologic, Inc.(a)
|
|
|
1,226
|
|
|
|
87,598
|
|
OraSure Technologies, Inc.(a)
|
|
|
18,631
|
|
|
|
152,774
|
|
QuidelOrtho Corp.(a)
|
|
|
6,612
|
|
|
|
487,304
|
|
|
|
|
|
|
|
|
826,286
|
|
Health Care Providers & Services - 15.1%
|
|
|
|
|
|
|
|
|
Enzo Biochem, Inc.(a)
|
|
|
12,801
|
|
|
|
17,793
|
|
Fulgent Genetics, Inc.(a)
|
|
|
7,513
|
|
|
|
217,201
|
|
Laboratory Corp. of America Holdings
|
|
|
3,143
|
|
|
|
714,372
|
|
OPKO Health, Inc.(a)
|
|
|
196,003
|
|
|
|
295,965
|
|
Quest Diagnostics, Inc.
|
|
|
4,967
|
|
|
|
684,850
|
|
|
|
|
|
|
|
|
1,930,181
|
|
Life Sciences Tools & Services - 5.2%
|
|
|
|
|
|
|
|
|
Adaptive Biotechnologies Corp.(a)
|
|
|
36,706
|
|
|
|
179,859
|
|
Gurnet Point Capital, LLC (a)(e)
|
|
|
16,557
|
|
|
|
1,325
|
|
Bio-Rad Laboratories, Inc. - Class A(a)
|
|
|
1,490
|
|
|
|
481,107
|
|
|
|
|
|
|
|
|
662,291
|
|
Pharmaceuticals - 5.9%
|
|
|
|
|
|
|
|
|
AN2 Therapeutics, Inc.(a)
|
|
|
7,541
|
|
|
|
154,515
|
|
Atea Pharmaceuticals, Inc.(a)
|
|
|
21,155
|
|
|
|
64,523
|
|
CorMedix, Inc.(a)(b)
|
|
|
13,897
|
|
|
|
52,253
|
|
Eli Lilly and Co.
|
|
|
148
|
|
|
|
86,272
|
|
Johnson & Johnson
|
|
|
565
|
|
|
|
88,558
|
|
Merck & Co., Inc.
|
|
|
853
|
|
|
|
92,994
|
|
Pfizer, Inc.(b)
|
|
|
2,868
|
|
|
|
82,570
|
|
Scilex Holding Co.(a)
|
|
|
16,596
|
|
|
|
33,855
|
|
SIGA Technologies, Inc.
|
|
|
18,025
|
|
|
|
100,940
|
|
|
|
|
|
|
|
|
756,480
|
|
Total United States
|
|
|
|
9,799,366
|
|
TOTAL COMMON STOCKS (Cost $25,723,315)
|
|
|
|
12,742,643
|
|
|
|
|
|
|
|
|
|
|
SHORT-TERM INVESTMENTS - 30.2%
|
|
|
|
|
|
|
|
|
Investments Purchased with Proceeds from Securities Lending - 29.9%
|
|
|
|
|
|
|
|
|
Mount Vernon Liquid Assets Portfolio, LLC, 5.61%(f)
|
|
|
3,827,986
|
|
|
|
3,827,986
|
|
|
|
|
|
|
|
|
|
|
Money Market Funds - 0.3%
|
|
|
|
|
|
|
|
|
First American Government Obligations Fund - Class X, 5.28%(f)
|
|
|
37,876
|
|
|
|
37,876
|
|
TOTAL SHORT-TERM INVESTMENTS (Cost $3,865,862)
|
|
|
|
3,865,862
|
|
|
|
|
|
|
|
|
|
|
TOTAL INVESTMENTS - 129.9% (Cost $29,589,177)
|
|
|
|
16,608,505
|
|
Liabilities in Excess of Other Assets - (29.9)%
|
|
|
|
(3,821,619
|
)
|
TOTAL NET ASSETS - 100.0%
|
|
|
|
|
|
$
|
12,786,886
|
|
|
|
|
|
|
|
|
|
|
Percentages are stated as a percent of net assets.
|
|
|
|
|
|
(a)
|
Non-income producing security.
|
(b)
|
All or a portion of this security is on loan as of December 31, 2023. The total market value of these securities was $3,626,361 which represented 28.4% of net assets.
|
(c)
|
To the extent that the Fund invests a significant portion of its assets in the securities of companies of a single country or region, it is more likely to be impacted by events or conditions
affecting the country or region.
|
(d)
|
To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those
industries or sectors.
|
(e)
|
Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Adviser, acting as Valuation Designee. These securities
represented $1,325 or 0.0% of net assets as of December 31, 2023.
|
(f)
|
The rate shown represents the 7-day effective yield as of December 31, 2023.
|
The following is a summary of significant accounting policies consistently followed by ETFMG Prime Junior Silver Miners ETF (“SILJ”), ETFMG Prime
Cyber Security ETF (“HACK”), ETFMG Prime Mobile Payments ETF (“IPAY”), ETFMG Travel Tech ETF (“AWAY”), ETFMG Treatments, Testing and Advancements ETF (“GERM”), ETFMG Alternative Harvest U.S. ETF (“MJUS”), ETFMG Alternative Harvest ETF (“MJ”),
ETFMG Wedbush ETFMG Video Game Tech ETF (“GAMR”), Wedbush ETFMG Global Cloud Technology ETF (“IVES”), BlueStar Israel Technology ETF (“ITEQ”), Etho Climate Leadership U.S. ETF (“ETHO”) and AI Powered Equity ETF (“AIEQ”)(each a “Fund,” or
collectively the “Funds”).
|
|
Security Valuation. Securities listed on a securities exchange, market or automated quotation system for
which quotations are readily available (except for securities traded on NASDAQ), including securities traded over the counter, are valued at the last quoted sale price on the primary exchange or market (foreign or domestic) on which they are
traded on the valuation date (or at approximately 4:00 pm Eastern Time if a security’s primary exchange is normally open at that time), or, if there is no such reported sale on the valuation date, at the most recent quoted bid price. For
securities traded on NASDAQ, the NASDAQ Official Closing Price will be used.
Securities for which quotations are not readily available are valued at their respective fair values as determined in good faith by ETF Managers Group, LLC (the
“Adviser”), using procedures adopted by the Board of Trustees (the “Board”). When a security is “fair valued,” consideration is given to the facts and
circumstances relevant to the particular situation, including a review of various factors set forth in the pricing procedures adopted by the Funds’ Board. The use of fair value pricing by a Fund may cause the net asset value of its shares
to differ significantly from the net asset value that would be calculated without regard to such considerations. As of December 31, 2023, AIEQ, HACK, AWAY, MJUS, IVES, ITEQ and ETHO did not hold any fair valued securities. As of
December 31, 2023, SILJ held three fair valued securities, IPAY, MJ, GERM, and GAMR held one fair valued security.
As described above, the Funds utilize various methods to measure the fair value of their investments on a recurring basis. U.S. GAAP establishes
a hierarchy that prioritizes inputs to valuation methods. The three levels of inputs are:
|